Supporting research in honor of our wives, mothers, sisters, and daughters.

The mission of the Marsha Rivkin Center is to save lives and reduce suffering through improved treatment, early detection and prevention of ovarian cancer.Join us in our resolute effort against ovarian cancer. We fund the best scientists, develop the brightest minds, and encourage the strongest research partnerships.

Support The MRC >

Events

Directions and Parking

Registration

	Thursday, October 28, 2010
	7:30-9:00	Poster Session
	9:00	Welcome
	9:10	Keynote Presentation Ovarian Cancer at Base Pair Resolution: Early Lessons and New Opportunities David Huntsman • University of British Columbia (Canada)
	9:35	Ovulation-related gene expression signatures in murine ovarian and oviduct epithelium reveals novel candidates associated with ovarian carcinoma Anna deFazio • Westmead Millennium Institute (Australia)
		FOXO3A loss is a key event in high-grade pelvic serous carcinogenesis Keren Levanon • Sheba Cancer Research Center (Israel)
		High resolution genome-wide SNP analysis of genetic alterations in early ovarian neoplasms Ian Campbell • Peter MacCallum Cancer Centre (Australia)
		Regulators of G-Protein Signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells by suppressing AKT survival pathways Shelley Hooks • University of Georgia
		Lysophosphatidic acid-dependent Bcl-2 production and secretion modulates angiogenesis Patricia Kruk • University of South Florida
	10:50	Break
	11:10	Role Of Intraoperative Cytology in the Evaluation of Fallopian Tubal Epithelium Santo Nicosia • University of South Florida
		Molecular Pathogenesis of Low-grade Serous Ovarian Cancer Kwong-Kwok Wong • Univ. of Texas, MD Anderson Cancer Center
		Tumor-associated Antigen C-Terminal Binding Protein-2 is Overexpressed in Epithelial Ovarian Tumors and Affects Response to HDAC inhibitors in vitro Lisa Barroilhet • Brigham and Women's Hospital
		Interleukin-8 and reactive oxygen species in ovarian tumor growth and angiogenesis Ling-Zhi Liu • Thomas Jefferson University
		Co-option of the human stimulatory NKG2D lymphocyte receptor as a tumor growth factor receptor Thomas Spies • Fred Hutchinson Cancer Research Center
	12:25	Poster Session and Lunch
	12:30-1:00	Clinical Spotlight Lecture: Can we define who will respond to PARP inhibitors? Karen Gelmon • University of British Columbia (Canada) and British Columbia Cancer Agency (Canada)
	1:30	Keynote Presentation Th17 Cells in Human Disease Weiping Zou • University of Michigan, Medical School
	1:55	Overcoming immune suppression in the ovarian cancer microenvironment by cytokine-mediated reprogramming of polyfunctional CD8+ T-cell responses Brad Nelson • British Columbia Cancer Agency (Canada)
		"DNA ends" induce DNA repair proteins responsible for intrinsic resistance to cisplatin to exit the Nucleolus Jean-Bernard Lazaro • Dana-Farber Cancer Institute
		Increasing ovarian carcinoma immunogenicity by 'silencing' the TGFb1 Gene Ingegerd Hellstrom • University of Washington
		The receptor tyrosine kinase axl is a therapeutic target for ovarian cancer Metastasis Katherine Fuh • Stanford University
	2:55	Break
	3:15	Novel mechanism for M2 polarization of tumor-infiltrating macrophages via GPI-anchored Proteins Nathalie Scholler • University of Pennsylvania School of Medicine
		Combination Therapies for Ovarian Cancer Improve Lifespan Janet Sawicki • Lankenau Institute for Medical Research
		Activation of NF-κB signaling by IKKβ increases aggressiveness of ovarian Cancer Christina Annunziata • National Cancer Institute
		Interferon-α plus regulatory T cell depletion to treat ovarian Cancer Tyler Curiel • UT Health Science Center
		Inhibitory B7 Family Members in Human Ovarian Carcinoma Ilona Kryczek • University of Michigan, Medical School
	4:30	Closing Remarks
	5:00	Shuttle to Space Needle Dinner
	6:00-9:00	Dinner Reception at Space Needle

	Friday, October 29, 2010
	7:30-9:00	Poster Session
	9:00	Welcome
	9:10	Keynote Presentation Cancer Biomarker Development - Making Progress...or Time Passed? Ernest Hawk • Univ. of Texas, MD Anderson Cancer Center
	9:35	Immune cell bound MUC16 (CA125): A novel diagnostic marker for ovarian cancer Manish Patankar • University of Wisconsin-Madison
		Overexpression of Pregnancy-associated Plasma Protein-A in Ovarian Cancer Cells Promotes Tumor Growth In Vivo Henning Boldt • Aarhus University (Denmark)
		MR Imaging of Ovarian Cancer with Folate-Receptor targeted Contrast Agents Sophie Boddington • Univeristy of California, San Francisco
		Unique methylation patterns in cell-free plasma DNA from women with malignant ovarian tumors Victor Levenson • Rush University Medical Center
		Prospectively using the ovarian cancer Symptoms Index in a primary care Setting M. Robyn Andersen • Fred Hutchinson Cancer Research Center
	10:50	Break
	11:10	S100A1 is a Prognostic Indicator of Relapse-Free Survival in Ovarian and Endometrial Endometrioid Carcinomas Kristin Boylan • University of Minnesota
		Functional Characterization of the Tumor Antigen Casein Kinase I-Epsilon in Ovarian Cancer Shu-Wing Ng • Brigham and Women's Hospital
		Blockade of the CXCL12/CXCR4 axis with a Small Molecule Antagonist Induces Multimodal Anti-tumor Effects in Murine Ovarian Cancer Resulting in Prolonged Survival Elda Righi • Massachusetts General Hospital
		Overexpression of nectin 4 in ovarian cancer tissues and sera: Potential role as a serum Biomarker Amy Skubitz • University of Minnesota
		sEGFR Is an Alternate Target of EGFR-directed Therapeutic Antibodies Jason Wilken • Yale School of Medicine
	12:25	Poster Session and Lunch
	12:30-1:00	Clinical Spotlight Lecture: Validation and Application of Serum Markers for Early Detection of Ovarian Cancer Nicole Urban • Fred Hutchinson Cancer Research Center
	1:30	Keynote Presentation Novel Therapeutics in Ovarian Cancer: Does the Emperor Have Clothes? Deborah Armstrong • Sidney Kimmel Comprehensive Cancer Center
	1:55	Myeloid-derived immune suppression in advanced ovarian cancer is regulated by a PD-1-mediated inhibitory Axis Keith Knutson • Mayo Clinic
		Bmi-1, a novel therapeutic target in ovarian Cancer Resham Bhattacharya • Mayo Clinic, Rochester
		Metformin Inhibits Ovarian Cancer Growth in Vivo Ramandeep Rattan • Mayo Clinic
		Self proteins of IGFBP-2 contain Class II epitopes that may preferentially induce a self regulatory Response Denise Cecil • University of Washington
	2:55	Break
	3:15	Robotic surgery for ovarian carcinoma: Outcomes and complications after the first 4 Years Dan Veljovich • Swedish Medical Center
		R1TRAIL and R1FasL: recombinant fusion proteins that redirect VEGF to actively kill cancer Cells Timothy Quinn • University of California San Francisco
		Xanthohumol decreases Notch1 expression and cell growth in human epithelial ovarian cancer cell Lines Jessica Drenzek • University of Wisconsin-Madison
		Secondary BRCA1/2 mutation as a mechanism of drug-resistance of BRCA1/2 mutated Cancer Toshi Taniguchi • Fred Hutchinson Cancer Research Center
		Formulation SEVIN-A composed of Pegylated-Nanoparticles of CDP bound to multitargeted siRNA molecules against BMI1 and Survivin conjugated with miR-373 which targets CD44 overexpressing cancer stem cells (CSCs) of metastatic ovarian carcinoma induces Apoptosis/PCD type I(D2 Stage) circumventing potent Chemoresistant-Multifactors caused by Vinorelbine John Giannios • Erasinio Oncology Hospital (Greece)
	4:30	Closing Remarks

Events

Poster Session

Welcome

Poster Session and Lunch

Closing Remarks

Shuttle to Space Needle Dinner

Dinner Reception at Space Needle

Poster Session

Welcome

Poster Session and Lunch

Closing Remarks